Cancer Immunotherapy
IMCAN
ADC-1013 and ADC-1014
Medical Need and Market Potential



Alligator Bioscience has developed a concept for IMmunotherapy of CANcer (IMCAN), providing powerful systemic anti-tumor effect with minimal systemic toxicity.

Cancer Immunotherapy

Immunoregulatory drugs have great potential for treatment of disseminated cancer as recently demonstrated by the FDA approval of Ipilimumab (Bristol-Myers Squibb) for the treatment of melanoma (1). Ipilimumab is an immune stimulatory antibody administered intravenously resulting in a systemic immune activation. However, systemic treatment with often causes toxic-side effects (60% immune related events, 1-2% deaths) that prohibit treatment of the patient with higher and potentially more optimal dose ranges. Alligator has developed a concept for immune therapy of cancer (IMCAN) to avoid systemic toxicity with retained or improved efficacy.

IMCAN (IMmunotherapy of CANcer)

By local administration of FIND^®-optimized immunoregulatory molecules, engineered for optimal function in the tumor environment, toxic side effects can be minimized and at the same time greater efficacy is obtained with the treatment. Local immunotherapy activates tumor-specific T-cells, resulting in efficient eradication of the treated tumor as well as distant metastases. Due to the local administration and lower total dose required, less systemic immune activation is induced, thereby minimizing the risk for toxicity.
IMCAN has been developed in collaboration with Professor Thomas Tötterman and his research group at Uppsala University, a pioneer in the field of local cancer immunotherapy, and researchers at Lund University.


ADC-1013 and ADC-1014

Alligator Bioscience has currently two IMCAN projects. ADC-1013 is an antibody-based immunotherapy for cancer. ADC-1014, is protein-based immunotherapy for cancer. For both development projects Proof-of-Concept have been demonstrated in animal models using different tumor types. The treatment concept is innovative and is expected to result in better efficacy and less adverse events compared to systemically administered immunotherapies.


Medical Need and Market Potential

Cancer is the second most common cause of death in the US and there is a high unmet medical need and urge for new therapies. The global market for cancer drugs was valued at over $50 billion in 2009 and is forecasted to grow at an annual growth rate of 8.4%, reaching almost $80 billion in 2015.